AUTHOR=König Enrico , Gagliardi Assunta , Riedmiller Ilary , Andretta Chiara , Tomasi Michele , Irene Carmela , Frattini Luca , Zanella Ilaria , Berti Francesco , Grandi Alberto , Caproni Elena , Fantappiè Laura , Grandi Guido 

TITLE=Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: The Staphylococcus aureus Case

JOURNAL=Frontiers in Immunology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.752168

DOI=10.3389/fimmu.2021.752168

ISSN=1664-3224

ABSTRACT=<p>Modification of surface antigens and differential expression of virulence factors are frequent strategies pathogens adopt to escape the host immune system. These escape mechanisms make pathogens a “moving target” for our immune system and represent a challenge for the development of vaccines, which require more than one antigen to be efficacious. Therefore, the availability of strategies, which simplify vaccine design, is highly desirable. Bacterial Outer Membrane Vesicles (OMVs) are a promising vaccine platform for their built-in adjuvanticity, ease of purification and flexibility to be engineered with foreign proteins. However, data on if and how OMVs can be engineered with multiple antigens is limited. In this work, we report a multi-antigen expression strategy based on the co-expression of two chimeras, each constituted by head-to-tail fusions of immunogenic proteins, in the same OMV-producing strain. We tested the strategy to develop a vaccine against <italic>Staphylococcus aureus</italic>, a Gram-positive human pathogen responsible for a large number of community and hospital-acquired diseases. Here we describe an OMV-based vaccine in which four <italic>S. aureus</italic> virulent factors, ClfA<sub>Y338A</sub>, LukE, SpA<sub>KKAA</sub> and Hla<sub>H35L</sub> have been co-expressed in the same OMVs (CLSH-OMVs<sub>Δ60</sub>). The vaccine elicited antigen-specific antibodies with functional activity, as judged by their capacity to promote opsonophagocytosis and to inhibit Hla-mediated hemolysis, LukED-mediated leukocyte killing, and ClfA-mediated <italic>S. aureus</italic> binding to fibrinogen. Mice vaccinated with CLSH-OMVs<sub>Δ60</sub> were robustly protected from <italic>S. aureus</italic> challenge in the skin, sepsis and kidney abscess models. This study not only describes a generalized approach to develop easy-to-produce and inexpensive multi-component vaccines, but also proposes a new tetravalent vaccine candidate ready to move to development.</p>